When the Evidence Aligns: Single-Dose Liposomal Amphotericin B for Cryptococcal Meningitis in High-Income Settings.

Lawrence DS, Jarvis JN

Open source

DOI
10.1093/cid/ciag487
Published
2026 Sep 17
Container
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciag487,
  title = {When the Evidence Aligns: Single-Dose Liposomal Amphotericin B for Cryptococcal Meningitis in High-Income Settings.},
  author = {Lawrence DS and Jarvis JN},
  year = {2026},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  doi = {10.1093/cid/ciag487},
  url = {https://doi.org/10.1093/cid/ciag487}
}

RIS

TY  - JOUR
TI  - When the Evidence Aligns: Single-Dose Liposomal Amphotericin B for Cryptococcal Meningitis in High-Income Settings.
AU  - Lawrence DS
AU  - Jarvis JN
PY  - 2026
JO  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DO  - 10.1093/cid/ciag487
UR  - https://doi.org/10.1093/cid/ciag487
ER  - 

APA

DS, L., & JN, J. (2026). When the Evidence Aligns: Single-Dose Liposomal Amphotericin B for Cryptococcal Meningitis in High-Income Settings.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciag487

Source records